Abstract
In the first part, this article review the accepted knowledge of type 1 diabetes, its physiopathology, the importance of cytokines and the induction of apoptosis and necrosis during its evolution. Throughout this work we describe in more detail the inhibition of this mechanism of cell destruction by acetyl-L-carnitine and nicotinamide. We also explain the complementary action of their association which gave support to the treatment. In the second part, we present the complete evolution of 8 children treated with the oral medication of 50 mg/Kg of acetyl-L-carnitine plus 25 mg/Kg of nicotinamide during 5 years. We published the first 2 years of evolution under treatment in these children (JPEM 26: 347, 2013). The children had positive auto-antibodies and were consanguineous of type 1 diabetic patients. The intravenous glucose tolerance test (IVGTT) showed a first phase of insulin release minor of 48 μU to enter in the protocol, and the same test was used for children evolution. Seven out eight children stopped the treatment because they normalized the metabolic parameters and no one became diabetic. All children increased the insulin response to IVGTT (between 1.44 to 5.69 times). Along the treatment, seven of these eight children turned their positive auto-antibodies into negatives.
Highlights
IntroductionThe number of diabetic patients was estimated in 366 million people by a recent report of the World Health Organization, and this population would be doubled by the year 2030, (http://www.idf.Org/ media-events/press-releases/2011/diabetes-atlas-5th-edition) reaching 552 million people and the estimated diabetes increment is 3% per year, with fluctuations among different countries
The number of diabetic patients was estimated in 366 million people by a recent report of the World Health Organization, and this population would be doubled by the year 2030, reaching 552 million people and the estimated diabetes increment is 3% per year, with fluctuations among different countries
We investigated if L-carnitine could modify the “in vitro” inhibition of insulin release of normal ß-cells when they were co-cultured with splenocytes from diabetic mice [81]
Summary
The number of diabetic patients was estimated in 366 million people by a recent report of the World Health Organization, and this population would be doubled by the year 2030, (http://www.idf.Org/ media-events/press-releases/2011/diabetes-atlas-5th-edition) reaching 552 million people and the estimated diabetes increment is 3% per year, with fluctuations among different countries. From all these patients, insulin-dependent diabetes represents 7-10% of established clinical diabetes, and type 1 diabetes is predominant in the infancy and adolescence, it can be present at every age. It is worth highlighting that a previous communication after short period of treatment has been published [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
